3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Conditions
Breast Neoplasms
72
Neoplasms
64
Prostatic Neoplasms
45
Colorectal Neoplasms
42
Lung Neoplasms
38
Carcinoma, Non-Small-Cell Lung
26
Pancreatic Neoplasms
21
Neoplasm Metastasis
20
Hematologic Neoplasms
20
Head and Neck Neoplasms
20
Urinary Bladder Neoplasms
15
Ovarian Neoplasms
14
Multiple Myeloma
11
Motor Activity
11
Leukemia, Myeloid, Acute
11
Stomach Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Uterine Cervical Neoplasms
9
Triple Negative Breast Neoplasms
9
Glioblastoma
9
Colonic Neoplasms
9
Hematopoietic and Lymphatic System Neoplasm
8
Glioma
8
Gastrointestinal Neoplasms
8
Carcinoma, Renal Cell
8
COVID-19
8
Anxiety Disorders
8
Anatomic Stage I Breast Cancer AJCC v8
8
Rectal Neoplasms
7
Melanoma
7
Interventions
Tea
3
Polyethylene Glycols
3
Infliximab
3
MEDI2070
2
Lidocaine
2
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
sodium phosphate
1
prucalopride
1
polyethylene glycol 400
1
picosulfate sodium
1
golimumab
1
cabozantinib
1
Surgical Tape
1
Standard of Care
1
Spectrum Analysis, Raman
1
Specimen Handling
1
Pneumococcal Vaccines
1
Platinum Compounds
1
Passive Cutaneous Anaphylaxis
1
Papillomavirus Vaccines
1
Oxygen
1
Nivolumab
1
Neomycin
1
Narrow Band Imaging
1
Morphine
1
Metronidazole
1
Medical Marijuana
1
Laparoscopy
1
Ipilimumab
1
Indocyanine Green
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Inflammatory Bowel Diseases
×
Standard of Care
×
Clear all
NCT06109961
2023-11-07
HYPNOTIC
Ottawa Hospital Research Institute
Phase 1/2
Unknown
40 enrolled